logo

For the Inventor, By the Inventor

Hangzhou, China

Ronghua Zhao

This inventor holds 7 USPTO granted patents and 3 published patent applications and 4 EPO patents. Top assignees: Hangzhou Converd Co., Ltd., Guangzhou Xiangxue Pharmaceutical Co., Ltd., Hangzhou Converd Co., Ltd.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronghua Zhao. Retrieved from https://idiyas.com/inventor/ronghua-zhao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 85.7

 

Average Co-Inventor Count = 4.8

ph-index = 1


Location History:

  • Zhejiang, CN (2021)
  • Hangzhou, CN (2021 - 2023)

Company Filing History:

goldMedal5 out of 8 
 
Hangzhou Converd Co., Ltd.
 patents
silverMedal2 out of 2 
 
Guangzhou Xiangxue Pharmaceutical Co., Ltd.
 patents
bronzeMedal1 out of 1 
 
Hangzhou Converd Co., Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents
1. 12653851 - ISOLATED RECOMBINANT ONCOLYTIC ADENOVIRUSES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF FOR DRUGS FOR TREATMENT OF TUMORS AND/OR CANCERS (2026-06-16),
2. 11806374 - Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancers (2023-11-07),
3. 11446345 - Therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancers (2022-09-20),
4. 11357804 - Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancers (2022-06-14),
5. 11071737 - Drug inclusion complex, preparation thereof, and preparation method thereof (2021-07-27),
6. 11007141 - Oral preparation and preparation method thereof (2021-05-18),
7. 10980859 - In vivo individualized systemic immunotherapeutic method and device (2021-04-20),

Title: Ronghua Zhao: Innovator in Oncolytic Virus Research

Introduction

Ronghua Zhao is a prominent inventor based in Hangzhou, China, known for his significant contributions to the field of oncolytic virus research. With a total of 7 patents, Zhao has focused on developing innovative therapeutic agents for the treatment of tumors and cancers.

Latest Patents

Zhao's latest patents include groundbreaking work on isolated recombinant oncolytic adenoviruses and pharmaceutical compositions aimed at treating tumors and cancers. One of his notable inventions is an isolated recombinant oncolytic adenovirus that selectively replicates in tumor cells while exhibiting limited replication in normal primary cells. This adenovirus is integrated with a coding sequence of exogenous shRNA that inhibits PDL1 expression in tumor cells. The combination of the oncolytic virus's killing effect and the immunostimulatory response from immune cells creates a synergistic effect, enhancing the overall therapeutic outcome.

Career Highlights

Throughout his career, Zhao has worked with several notable companies, including Hangzhou Converd Co., Ltd. and Guangzhou Xiangxue Pharmaceutical Co., Ltd. His work has significantly advanced the understanding and application of oncolytic viruses in cancer treatment.

Collaborations

Zhao has collaborated with esteemed colleagues such as Fang Hu and Lin Chen, contributing to the collective knowledge and innovation in the field of cancer therapeutics.

Conclusion

Ronghua Zhao's innovative work in oncolytic virus research and his numerous patents highlight his dedication to advancing cancer treatment. His contributions continue to pave the way for new therapeutic strategies in oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…